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Summary The most effective post-remission treatment to
maintain complete remission (CR) in adults aged between
46 and 60 years with acute myeloid leukaemia (AML) is
uncertain. Previously untreated patients with AML in CR
after induction chemotherapy with daunorubicin and
cytarabine were randomized between two intensive courses
of consolidation therapy containing high-dose cytarabine,
combined with amsacrine or daunorubicin and a standard
consolidation and maintenance therapy containing standard
dose cytarabine and daunorubicin. One hundred fifty-eight
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DOI 10.1007/s00277-012-1436-zCR patients were assigned to the intensive group and 157
patients to the standard group. After a median follow-up of
7.5 years, the 4-year survival rate was 32 % in the intensive
group versus 34 % in the standard group (P00.29). In the
intensive group, the 4-year relapse incidence was lower than
in the standard group: 55 and 75 %, respectively (P0
0.0003), whereas treatment-related mortality incidence was
higher: 22 versus 3 % (P<0.0001). Two intensive consoli-
dation courses containing high-dose cytarabine as post-
remission treatment in patients with AML aged between
46 and 60 years old did not translate in better long-term
outcome despite a 20 % lower relapse incidence. Better sup-
portivecareandpreventionoftreatment-relatedcomplications
may improve the overall survival after intensified post-
remission therapy in this age group.
Keywords Acutemyeloidleukaemia.Post-remission
chemotherapy
Introduction
Patients, younger than age 60 years, with acute myeloid leu-
kaemia (AML) may achieve complete remission (CR) in 60 to
80 % of the cases treated with intensive remission induction
courses usually consisting cytarabine (Ara-C) combined with
an anthracycline/anthracycline-like drug [1–5]. Following re-
mission induction therapy, additionaltreatment is important, as
the median relapse-free survival (RFS) for patients who do not
receive additional therapy is only 4–8m o n t h s[ 4]. Therefore,
most patients receive post-remission therapy, which may con-
sist of consolidation/maintenance chemotherapy, autologous
or allogeneic stem cell transplantation [2–4]. Both allogeneic
and autologous stem cell transplantation is associated with
higher treatment-related morbidity and mortality patients with
the agebetween 46 and 60yearscompared to younger patients
[6]. Therefore these patients are usually treated with consoli-
dation and/or maintenance chemotherapy only [2, 4]. Despite
manystudiesonpost-remissiontherapytopreventrelapsewith
chemotherapy with maximal efficiency and minimal toxicity,
an effective schedule for this age group has not been estab-
lished until now [2, 4, 7–15].
Cytarabine plays a central role in the post-remission
treatment of AML, but exact doses and number of cycles
have not been defined yet [2, 4]. Cytarabine has a steep
dose–response curve, which stimulated many study groups
to verify this effect in prospective trials on post-remission
treatment of AML [2, 8, 10, 14–21]. The European Organi-
zation for Research and Treatment of Cancer (EORTC) and
the Gruppo Italiano Malattie Ematologiche Maligne dell’A-
dulto (GIMEMA) Leukemia Cooperative Groups developed
a prospective randomized phase III trial in patients with
AML aged between 46 and 60 years, to test two different
dosages of cytarabine in post-remission treatment. All
patients received induction therapy consisting of a combi-
nation of cytarabine and daunorubicin after which they were
randomly assigned to receive two courses of intensive con-
solidation therapy containing high-dose cytarabine, com-
bined with either amsacrine or daunorubicin or to receive a
standard consolidation and maintenance course containing
standard dose cytarabine and daunorubicin. The group per-
formed simultaneously a study in patients younger than
45 years on the role of allogeneic and autologous stem cell
transplantation after intensive consolidation chemotherapy
alone [22].
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Patients
Patients with previously untreated acute myeloid leukae-
mia were eligible for entry into the trial. The diagnosis
was made by the participating centres according to the
criteria of the French–American–British (FAB) classifi-
cation system [23]. A cytology committee reviewed the
smears from 53 % of patients. Patients with age be-
tween 46 and 60 years were eligible, but some centres
which did not perform stem cell transplantation were
allowed to enrol younger patients. Informed consent
was obtained according to the regulations of each insti-
tution. Patients with chronic myeloid leukaemia or other
myeloproliferative diseases in blast crisis were excluded,
as were patients who had leukaemia supervening after
other myeloproliferative diseases or patients who had a
preceding myelodysplastic syndrome for more than
6 months. Most centres excluded patients with acute
promyelocytic (M3) leukaemia. Patients with concomi-
tant hepatic, renal, cardiac or neurological disease or
patients with other progressive malignant diseases have
been excluded as well.
Study design
The induction treatment consisted of one course, or in case
of partial remission, two courses, consisting of daunorubi-
cin, at a dose of 45 mg/m
2 of body surface area, given
intravenously as a push infusion on days 1, 2 and 3 and
cytarabine at a daily dose of 200 mg/m
2 given as a contin-
uous intravenous infusion on days 1 through 7. In case of
leukemic regrowth, absolute resistance or persistent hypo-
plasia, a salvage scheme was used, which consisted of
idarubicin, at a dose of 12 mg/m
2 of body surface area given
as a continuous infusion on days 1, 3 and 5, and cytarabine
at a dose of 500 mg/m
2 given as a continuous intravenous
infusion over a period of 2 h every 12 h on days 1 through 7
[24].
All patients who achieved complete remission were ran-
domized between short intensive consolidation therapy or
standard consolidation and maintenance therapy, except 17
patients who participated to an amendment of the trial to
study the role of GM-CSF during remission induction ther-
apy [25]. For details, see Fig. 1.
Short intensive consolidation treatment consisted of two
courses. The first course contained cytarabine, at a dose of
500 mg/m
2 of body surface given as a continuous
Repeated salvage 
scheme if: PR  Intensive 
consolidation therapy: 
IC1 + IC2 
158 
Standard
consolidation and 
maintenance therapy 
157 
Remission-Induction 
N = 603  
Repeated induction 
scheme if: partial 
remission (PR) 
Complete Remission (CR) 
367  
Salvage scheme if: 
therapy resistance of 
PR or leukaemic 
regrowth, absolute 
resistance or persistent 
Randomization 
315 
Reasons for exclusion from 
randomization: 
Refusal:    14 
Excessive Toxicity:    23
Early relapse:       4
Protocol violation:    8
Loss to follow-up or other: 3
Registration 
N = 659 
Ineligible: 15 patients 
Not evaluable: 41 patients# 
Fig. 1 Design of the study. The
numbers are the numbers of
patients at each treatment step.
Details of the treatment are
given in the “Methods” section.
The 659 registered patients
included 37 patients who
participated to the GM-CSF
study [25]. Seventeen patients
have been randomized, but they
have not been included in this
study. Of 603 patients, 367
reached CR, 157 patients were
excluded because they did not
reach CR and 79 patients died
before they could reach CR.
IC1 first course of intensive
treatment schedule. IC2 second
course of intensive treatment
schedule
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days 1 through 6, and amsacrine at a dose of 120 mg/m
2,
given in a 3-h intravenous infusion on days 5, 6 and 7. The
second course contained cytarabine at a dose of 2 g/m
2
given in an intravenous infusion over a period of 2 h every
12 h on days 1 through 4 and daunorubicin at a dose of
45 mg/m
2 given as a push infusion on days 5, 6 and 7. The
dose of cytarabine was limited to 2 g/m
2 to decrease the risk
of cerebellar toxicity.
Standard consolidation maintenance treatment consisted
of two parts. The consolidation treatment consisted of one
course with cytarabine at a dose of 200 mg/m
2 given as a
continuous infusion on days 1 through 7 and daunorubicin
at a dose of 45 mg/m
2 given as a push infusion on day 1.
The maintenance treatment consisted of six courses with
daunorubicin at a dose of 45 mg/m
2 given as a push intra-
venous infusion on day 1 and cytarabine at a dose of
100 mg/m
2 given subcutaneously every 12 h on days 1
through 5, given at 4- to 6-week intervals.
The Italian centres used a similar standard consolidation/
maintenance treatment which consisted of four courses
which contained daunorubicin at a dose of 60 mg/m
2, given
intravenously on day 1; cytarabine at a dose of 60 mg/m
2,
given subcutaneously every 8 h on days 1 till 5 and thio-
guanine at a dose of 70 mg/m
2 of body surface area, orally
every 8 h on days 1 till 5. Sequential courses were given
with 4-week intervals. Several Italian centres without trans-
plant facilities elected to include patients younger 46 years.
Criteria for evaluation
A complete remission (CR) was defined according to the
criteria of the CALGB [26]. Both bone marrow and periph-
eral blood should remain normal for at least 1 month. Leu-
kemic cell infiltrations of the skin or of other sites should
not be present. A partial remission (PR) was defined as a
reduction of marrow blasts of at least 50 and 5.1–25 %
marrow blasts with <5 % circulating blasts. A complete
remission lasting less than 1 month was classified as a PR.
Relapse was defined as more than 10 % leukemic cells in
bone marrow aspirates or new extramedullary leukaemia in
patients with a previously documented CR. Extramedullary
relapse should be defined by cytology or histology.
Statistical considerations
All patients were prospectively registered at the EORTC
Data Centre in Brussels, and those considered to fulfil
eligibility criteria for randomization after the achievement
of complete remission were allocated to receive either stan-
dard consolidation and maintenance therapy (control arm) or
short intensive consolidation therapy (experimental arm).
The primary objectives of the study were to assess the value
of short intensive consolidation chemotherapy versus a stan-
dard maintenance therapy in terms of RFS and overall
survival (OS). The secondary objectives were to assess
toxicities of these two types of post-remission therapy. A
total of 300 patients had to be randomized in order to
observe 182 events (relapses or deaths) which would allow
to detect an increase from 25 to 40 % of patients alive and
without relapse at 3 years, corresponding to a hazard ratio
(HR; ratio of the instantaneous event rate in the experimen-
tal group versus the control group) of 0.66. RFS was calcu-
lated from the date of randomization until the date of the
first relapse or the date of death in first complete remission.
The OS was defined as the length of time from the date of
randomization to the date of death. Survival distributions
were estimated according to the Kaplan–Meier technique,
and the standard errors (SE) of the estimates were obtained
using Greenwood’s formula [27]. The differences between
curves were tested for statistical significance with the two-
tailed log-rank test [27]. The Cox’s proportional hazards
model was used to obtain the estimate and the 95 % confi-
dence interval (CI) of the HR [27]. Competing risk methods
were used to estimate the incidences of relapse and of death
in CR along with their SEs, and to perform their comparison
(the Gray test) [27]. All randomized patients were analysed
in their respective treatment groups in order to adhere to the
intention-to-treat principle.
Results
Between November 1986 and April 1993, 659 patients have
been registered in the study by 44 institutions. Figure 1
shows the flow chart of the study. Fifteen patients were
ineligible (6 patients because of chronic myeloid leukaemia,
1 patient because of blast crisis, 1 because of myelodys-
plastic syndrome with a duration longer than 6 months, 4
because of other diseases which met the exclusion criteria, 1
because the age did not fulfil the inclusion criteria and 2
because of other malignancies), and 41 patients could not be
evaluated, including 37 patients who participated to the
GM-CSF study [25]. Thus, a total of 603 patients were
evaluable. The distribution according to population charac-
teristics is shown in Table 1. The median age was 52 years
(ranging from 13 to 60 years), including 36 patients (12 %)
younger than 46 years. The ratio of male to female patients
was 1.03. The distribution of the morphologic types of AML
according to the FAB classification is shown in Table 1.
CR was achieved in 367 patients (61 %), and most
remissions (81 %) were reached after one course of induc-
tion therapy. In addition, 157 patients did not achieve CR
(26 %) and 79 patients died before evaluation of response
(13 %). Out of 367 CR patients, 52 have not been random-
ized (for details, see Fig. 1). Finally, 315 patients were
828 Ann Hematol (2012) 91:825–835randomly assigned to two groups: 158 patients for the short
intensive consolidation therapy and 157 for the standard
consolidation and maintenance therapy. Table 1 shows the
patient characteristics in both randomized groups. The pa-
tient and disease characteristics (i.e. age, sex, FAB classifi-
cation, WBC and platelets on admission, cytogenetics)
which have been reported to be of prognostic value were
similar in the two treatment arms, except for the number of
courses needed to reach CR, which favoured the intensive
consolidation group [3]. In the intensive group, 149 (94 %)
patients started the allocated treatment, 3 received standard
consolidation/maintenance, 1 received another treatment
and 5 received no treatment at all, whereas in the standard
group 151 (96 %) patients started the allocated treatment, 3
received the intensive treatment and 4 received no treatment.
The number of patients who completed their assigned treat-
ment were 89 (56 %) in the intensive consolidation group
and 104 (66 %) in the standard consolidation and mainte-
nance group. Reasons for exclusion or not completing the
assigned treatment in the two randomized arms are outlined
in Table 2. Early relapse occurred more frequently in the
standard group, whereas toxicity and refusal were more
frequent in the intensive group. All patients were maintained
in their assigned group for the analysis of the results to
comply with the intention-to-treat principle.
Table 3 shows the rates of relapse and of death in CR as a
first event, along with the corresponding causes of death,
according to both treatment groups. When comparing the
intensive with standard group, the relapse rate was higher in
the standard group, whereas the death rate in CR in the
Table 1 Characteristics of study
population (603 patients) and of
patients who were randomized,
by treatment arm
aGood prognosis0t(8;21), t
(15;17), inv16. Intermediate
prognosis0normal metaphases
and –Y. Poor prognosis0trisomy
8, 5q-, monosomy 5 and 7 and
all other cytogenetic abnormali-
ties, including complex
abnormalities
Characteristic Total population,
N (%)
Randomized
Intensive therapy, N (%) Standard therapy, N (%)
Age (years)
<46 72 (12) 18 (11) 18 (12)
46–55 363 (60) 93 (66) 104 (59)
56–60 168 (28) 47 (30) 35 (22)
Sex
Male 307 (51) 81 (51) 78 (50)
Female
FAB type
M1 106 (18) 26 (17) 24 (15)
M2 187 (31) 48 (30) 43 (27)
M3 15 (2) 3 (2) 2 (1)
M4 140 (23) 46 (29) 43 (27)
M5 115 (19) 26 (17) 37 (24)
M6 33 (5) 9 (6) 8 (5)
M7 3 (1) ––
White cell count×10
9/L at diagnosis
<25 363 (60) 97 (61) 94 (60)
25–100 168 (28) 46 (29) 45 (29)
≥100 72 (12) 15 (10) 18 (12)
Platelet count×10
9/L at diagnosis
<50 282 (48) 75 (48) 80 (51)
≤50 321 (53) 83 (53) 77 (49)
Cytogenetic group
a
Good 18 (3) 9 (6) 7 (4)
Intermediate 92 (15) 28 (18) 26 (17)
Poor 46 (8) 13 (8) 9 (6)
Inconclusive 447 (74) 108 (68) 115 (73)
No. of courses needed to reach CR
1 297 (81) 134 (85) 122 (78)
>1 70 (19) 24 (15) 35 (22)
Total 603 (100) 158 (100) 157 (100)
Ann Hematol (2012) 91:825–835 829intensive group exceeded the rate of the standard group. The
main cause of death in CR was infection. Grades 3 and 4
toxicities occurred more frequently in the intensive consol-
idation arm despite the shorter treatment period of this arm
(Table 4). Especially toxicities related to the more profound
cytopenias, such as infections and haemorrhages, were in-
creased in the intensive consolidation arm.
The median length of follow-up of surviving patients was
7.5 years. At 4 years after randomization, the probability of
RFS in the intensive group was 24 % (SE 3 %) and 22 %
(SE 3 %) in the standard group. Figure 2 shows the Kaplan–
Meier curves of the two groups. There was no significant
difference among the two groups (P00.49 by the log-rank
test): HR, 1.09 (95 % CI 0.85 to 1.40). Figure 3 shows a
lower 4-year relapse incidence rate in the intensive group
than in the standard group: 55 % (SE 4 %) versus 75 % (SE
4% ;P00.0003). Figure 4 indicates that the 4-year incidence
of death in first CR was 22 % (SE 3 %) in the intensive
group and 3 % (SE 1 %) in the standard group (P<0.0001).
The treatment HR regarding the risk of relapse was 0.83 (95
% CI 0.63 to 1.09), and regarding the risk of death in CR
was 7.3 (95 % CI 2.9 to 18.8). At 4 years, the probability of
survival in the intensive group was 32 % (SE 4 %) and 34 %
(SE 4 %) in the standard group. There was no significant
difference among the two groups (Fig. 5, P00.29 by the log-
rank test; HR 1.15, 95 % CI 0.89 to 1.49). After exclusion of
the 36 patients younger than 46 years, in the remaining 279
patients aged 46 to 60 years, the OS difference between both
groups (intensive versus standard consolidation) remained
unchanged: HR 1.07, 95 % CI 0.75 to 1.54; P00.61. Anal-
yses adjusted for the slight treatment imbalance regarding
the number of courses to reach CR provided very similar
results (data not shown). The median survival after relapse
was 6 months in both arms with 12 % alive at 4 years after
relapse in the standard arm and 11 % in the intensive
consolidation arm (HR 0.99; 95 % CI 0.74 to 1.32).
Subsequent analyses for exploratory purposes with sub-
groups were performed. The comparison of overall survival
of a high-risk group, consisting of randomized patients older
than 55 years, who needed more than one course of induc-
tion treatment to reach CR and who did have a high WBC
count (>100×10
9/L) with the standard risk group (other
randomized patients). In the latter group (173 patients), the
intensive arm resulted in a 34 % 4-year survival rate com-
pared to 43 % in the standard consolidation arm (HR, 1.32;
95 % CI 0.92 to 1.90; P00.13), while in the high-risk group
(142 patients) the outcome was reverse: 4-year survival rate
of 30 % in intensive arm versus 23 % in the standard arm
(HR, 0.96; 95 % CI 0.66 to 1.40; P00.83).
We did not evaluate cytogenetic characteristics separately
because of the insufficient number of patients with known
cytogenetic profiles. Comparisons according to whether
patients were treated in EORTC centres or in GIMEMA
centres have been performed as well. Patients (N065)
Table 2 Reasons for going off-
protocol treatment at each step
according to the randomized
treatment arm
Category Intensive consolidation
group (N0158), n (%)
Standard consolidation and
maintenance group (N0157), n (%)
Normal completion of assigned treatment 89 (56) 104 (66)
Reasons for going off-protocol treatment
Early relapse 6 (4) 31 (20)
Toxic effect 48 (31) 10 (6)
Refusal to undergo treatment 10 (6) 3 (2)
Protocol violation 3 (2) 7 (4)
Loss to follow-up or other reason 2 (1) 2 (1)
Table 3 Type of first events (relapse or death in first CR) according to
the randomized treatment arms
Category Randomized intensive
therapy (N0158), n (%)
Randomized standard
therapy (N0157), n (%)
Relapse of leukaemia 91 (58) 121 (77)
Death during first CR 34 (22) 5 (3)
Causes of death
Infection 16 (10) 3 (2)
Bleeding complications 11 (7) –
Other 7 (4) 2 (1)
Alive in first CR 33 (21) 31 (20)
Table 4 Grade 3 and grade 4 toxicities observed during therapy in
both treatment arms
Category grade
3/4
Intensive therapy (N0158),
n (%)
Standard therapy (N0
157), n (%)
Haemorrhage 17 (11) 3 (2)
Infections 43 (28) 12 (8)
Liver 12 (8) 10 (7)
Nausea,
vomiting
22 (15) 10 (7)
Diarrhoea 6 (4) 1 (1)
Renal 3 (2) 0 (0)
Cardiac 8 (5) 1 (1)
Neurotoxic 4 (3) 1 (1)
830 Ann Hematol (2012) 91:825–835treated in the EORTC centres showed a trend in favour of
intensive versus standard arm either in terms of RFS (HR,
0.88) and OS (HR, 0.78). In GIMEMA centres the reduction
in relapse incidence could not be compensated by the in-
crease in TRM observed in the intensive versus standard
arm, resulting in an HR of 1.14 regarding RFS and an HR
1.25 regarding OS. The standard consolidation and mainte-
nance arm differed between the two cooperative groups
leading to a total dose of 7.4 g cytarabine in the EORTC
centres versus 3.6 g in the GIMEMA centres and a dose of
315 mg and 240 mg daunorubicin, respectively, while the
Italian patients received additional thioguanine. The 4-year
OS rate of 124 Italian patients and the 33 EORTC patients
was completely identical: 34 % in both groups. We also
performed analyses to test whether a learning effect in time
existed. Dividing the group of randomized patients in two
equal cohorts according to the period of randomization, the
treatment comparison regarding RFS and OS remained un-
changed (data not shown).
Discussion
This study did not show a survival advantage of treatment
with two intensive consolidation courses containing high-
dose cytarabine, when compared with a regimen consisting
of standard consolidation and six maintenance courses con-
taining standard dose cytarabine. The Italian patients in this
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Fig. 3 Cumulative incidence of relapse according to randomized arm.
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treatment. The 4-year survival of the 33 patients in the
EORTC and the 124 patients in the GIMEMA centres trea-
ted with standard consolidation and maintenance therapy
was 34 % (SE 8 %) and 34 % (SE 4 %), respectively. The
toxicity patterns of both standard consolidation/maintenance
regimens were very similar as well (data not shown). There-
fore, all patients were analysed in the assigned group. The 4-
year leukaemia relapse incidence was significantly (P0
0.0003) lower in the intensified regimen group (55 %)
compared to the less intensive standard group (75 %), con-
firming the higher anti-leukemic activity of the intensive
consolidation courses. Nevertheless, the higher toxicity of
the intensified treatment led to a significantly higher mor-
tality incidence in first CR (22 % versus 3 %; P<0.0001).
Because of this high toxicity, 31 % of patients in the inten-
sive group did not finish the complete schedule, in contrast
to only 6 % of patients in the group treated with standard
post-remission chemotherapy. In the parallel study of the
EORTC and GIMEMA Cooperative Leukemia Groups in a
younger age group of 576 patients with a median age
33 years, the dropout due to toxicity after IC1 was only 18
% compared to 27 % (42 patients) after IC1 in patients older
than 45 years in this study [22]. This indicates that admin-
istration of intensive consolidation courses is more problem-
atic in patients older than 45 years. A limited number of
studies addressed the impact of dose escalation of cytarabine
as post-remission treatment in AML in this specific age
group. Cassileth et al. showed that the combination of
amsacrine and high-dose cytarabine as a single-course
post-remission treatment, resulted in a higher event-free
survival and better overall survival (only significant in
patients younger than 41 years) than standard maintenance
therapy, but this regimen exhibited high toxicity, especially
in older patients [16]. Fopp et al. showed that one cycle of
high-dose cytarabine in post-remission treatment, when
compared to one cycle of standard dose cytarabine,
exhibited a significantly higher RFS in patients older than
40 years and reduced the hazard of relapse [20]. This study
also showed a trend for improved survival using one cycle
of high-dose cytarabine. Both arms included daunomycin in
the consolidation courses [20]. Because only one cycle of
post-remission treatment was shown to be effective, more
patients could tolerate the adverse effects of treatment [17,
20]. In contrast, Weick et al. observed that consolidation
with high-dose cytarabine increased toxicity, but this ap-
proach did not improve OS or RFS compared to consolida-
tion with standard dose cytarabine [19]. In this Southwest
Oncology Group study, cytarabine was combined with dau-
norubicin in all schedules. Bradstock et al. evaluated the
difference between high-dose cytarabine versus low or stan-
dard dose cytarabine as a consolidation treatment, after CR
induction containing high-dose cytarabine, and they showed
no difference for survival, relapse-free survival at 3 years or
cumulative incidence of relapse. The high-dose cytarabine
arm consisted of one course only and the standard cytara-
bine arm of two courses only, fewer courses than adminis-
tered in most protocols. Cytarabine was combined with
idarubicin and etoposide in all courses [8]. This study did
not demonstrate a benefit of the intensive consolidation arm
in any of the three cytogenetic groups [8]. Büchner et al.
compared after three intensive courses of remission induc-
tion and consolidation therapy the efficacy of 3-year main-
tenance versus only one additional intensive consolidation
course containing high-dose Ara-C. Patients treated with 3-
year maintenance seem to benefit in terms of a better RFS,
but the OS was not different in both groups [28]. In our
study we could not use cytogenetic nor molecular character-
istics as discriminating prognostic factor between short in-
tensive and prolonged nonintensive post-remission
treatment which might lead to certain imbalances. A few
studies indicated that non-poor risk cytogenetic character-
istics may favour intensive consolidation [18, 28], similarly
to the more favourable response after adding anti-CD33
immunotoxin conjugate gentuzimab–ozogamicin to remis-
sion or consolidation courses in the favourable or interme-
diate risk cytogenetic groups [29].
Currently, several alternative treatment modalities may
be considered for the patient population older than 45 years
of age. Recently, escalation of the dose of daunorubicin to
twice the conventional dose in the remission induction
schedule of AML patients older than 60 years resulted in
an increased overall survival in the age cohort between 60
and 65 years [30, 31]. Incorporation of this escalated dose of
daunorubicin in the post-remission therapy is a challenging
option, but increased cardiotoxicity may result from this
dose intensification [30]. GO has been used as single agent
for post-remission therapy in AML patients older than
60 years. GO post-remission therapy consisted of three
courses GO (6 mg/m
2) every 4 weeks. Only 65 of the 113
patients completed the three courses. The 5-year RFS was
17 % in the GO arm versus 16 % in the 119 patients who did
not receive any post-remission therapy [32].
Autologous peripheral stem cell transplantation might be
an interesting treatment modality [33]. Using this approach,
the haematological recovery is quite fast, while this treat-
ment exhibits the outcome advantages of transplantation. In
the AML 10 study of the EORTC and GIMEMA LCG [34],
one of the three arms used daunorubicin as anthracycline,
but the patients without a donor received an autologous stem
cell transplantation after the first consolidation course which
was identical to the intensive consolidation course of the
AML 8B study. The 4-year survival rate of the 148 patients
in the same age group (46 to 60 years) without an HLA
identical sibling and randomized for daunorubicin was 36 %
(SE 4.0 %), similar to the 4-year survival rate, and 32 % (SE
832 Ann Hematol (2012) 91:825–8354 %) observed in the intensive arm of this study. This
indicates that replacement of the second consolidation
course by autologous stem cell transplantation has no major
impact on long-term survival as observed in the randomized
AML 8a study performed at the same time in a younger age
cohort [22]. Another promising treatment modality nowa-
days is reduced intensity conditioning allogeneic stem cell
transplantation, which has the aim to exhibit the well-
documented immune graft versus tumour effect, while
attempting to control or to overcome toxicity. Promising
results have been shown in patients with AML older than
50 years [35]. Prospective randomized studies are needed to
verify this effect.
In conclusion this study showed that the lower relapse
rate when using intensified post-remission treatment in
patients with AML aged between 46 and 60 years was
counterbalanced by higher toxicity. Future prospective stud-
ies should focus on the use of high-dose therapy consisting
of a limited number of courses with attention to optimal
supportive care and differences in outcome according to
prognostic factors, especially cytogenetic profiles, as a re-
sult of which possibly intensive treatment could become the
treatment of choice. Alternative treatment modalities as
post-remission treatment, especially autologous peripheral
blood stem cell transplantation and reduced intensity condi-
tioning allogeneic stem cell transplantation, should be tested
in the framework of prospective randomized trials. More-
over various prognostic factors, especially cytogenetic and
molecular characteristics, should identify patients who may
benefit of the treatment intensified by increased dosages of
cytarabine and anthracyclines.
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Appendix
The following centres and investigators from the EORTC
Leukaemia Cooperative Group participated in this study:
Austria—Innsbruck, University Klinik, (J. Thaler); Bel-
gium—Brugge, Hospital St. Jan (D. Selleslag); Brussel
Hospital Bordet-Erasme(W. Ferremans); France—Nice,
Centre Antoine Lacassagne (A Thyss); Paris, Hospital
Hotel-Dieu (J-P Marie, A. Vekhoff); Villejuif, Institut
Gustave Roussy (M. Hayat); The Netherlands—Enschede,
Medisch Spectrum Twente (M. Schaafsma); Hertogenbosch,
Jeroen Bosch Ziekenhuis (J. Burghouts); Nijmegen, Rad-
boud University Medical Centre (T. de Witte, P. Muus);
Amsterdam, Onze Lieve Vrouw Gasthuis (B. De Valk);
Portugal—Coimbra, Institute of Oncology (G. Teixeira);
Porto, San Joao (M. Ribeiro); and Turkey—Ankara, Ibnui
Sina Hospital (M.Beksac), Germany: Heidelberg, Kopfkli-
nik,(A. Ho?), Croatia, Zagreb, Hopital Rebro (B. Labar),
Hospital Merkur (B. Jaksic). The following centres and
investigators from the GIMEMA group participated in this
study: Italy—Reggio Calabria, Dipartimento Emato-
Oncologia A.O. “Bianchi-Melacrino-Morelli” (A. Neri);
Roma, U.O.C. Ematologia—Ospedale S.Eugenio (G. Papa);
Roma, Università degli Studi “Sapienza”—Dip Biotecnolo-
gie Cellulari ed Ematologia—Divisione di Ematologia (F.
Mandelli); Roma, Università Cattolica del Sacro Cuore—
Policlinico A. Gemelli (B. Bizzi); Roma, Divisione di Ema-
tologia—Ospedale S. Camillo (A. De Laurenzi); Palermo,
Azienda Ospedaliera—Policlinico Divisione di Ematologia
(P. Citarrella); Palermo, Div. di Ematologia—A.O. “V. Cer-
vello” (F. Caronia); Palermo, Divisione di Ematologia con
trapianto di midollo—Università degli Studi di Palermo—
A.U. Policlinico ( A. Cajozzo); Parma, Cattedra di Emato-
logia CTMO Università degli Studi di Parma (V. Rizzoli);
Pavia, Div. di Ematologia IRCCS Policlinico S. Matteo (c.
Bernasconi); Nuoro, Sez. di Ematologia Clinica Ospedale
San Francesco (A. Gabbas); Ancona, Clinica di Ematologia,
Osp. Riuniti di Ancona (P. Leoni); Torino, Div. di Emato-
logia “Molinette” Osp. Maggiore S. G. Battista (L. Rese-
gotti, A. Pileri); Perugia, Sezione Ematologia ed
Immunologia Clinica—Ospedale S.Maria della Misericor-
dia (F. Grignani); Aviano, Centro di Riferimento Oncolo-
gico (S. Monfardini); S.G. Rotondo, Istituto di Ematologia
—IRCCS Ospedale Casa Sollievo della Sofferenza (M.
Carotenuto); Latina, Divisione di Ematologia Ospedale
“Santa Maria Goretti” (L. Deriu); Pesaro, Div. di Ematolo-
gia di Muraglia—CTMO Ospedale San Salvatore (G. Lucar-
elli); Bari, Unità Operativa Ematologia 1—Università degli
Studi di Bari—Padiglione Chini—3°piano (V. Liso), Cata-
nzaro, Azienda Ospedaliera Pugliese Ciaccio—Presidio
Ospedaliero A. Pugliese—Unità Operativa di Ematologia
(A. Alberti); Avellino, Az.Ospedaliera S.G.Moscati
(E.Volpe); Milano, Ospedale Niguarda “Ca Granda” (F. De
Cataldo); Napoli, A.S.L. Napoli 1 Ospedale San Giovanni
Bosco (R. De Biasi); Napoli, Azienda Ospedaliera
Universitaria-Università degli Studi di Napoli “Federico
II”—Facoltà di Medicina e Chirurgia (B. Rotoli); Napoli,
Azienda Ospedaliera di Rilievo Nazionale “A. Cardarelli”
(R. Cimino); Cagliari, ASL N.8—Ospedale “A. Businco”—
Unità Operativa di Ematologia e Trapianto di Midollo (G.
Broccia); Pescara, U.O. Ematologia Clinica—Azienda USL
di Pescara (G. Torlontano); Potenza, Ematologia—Ospedale
Ann Hematol (2012) 91:825–835 833San Carlo (F. Ricciuti); Sassari, Serv. di Ematologia Ist. di
Ematologia ed Endocrinologia (M. Longinotti); Cremona,
Sezione di Ematologia C.T.M.O. Istituti Ospitalieri, (E.
Bianchini). Cytology committee: M. Cadiou, M. Bernier,
G. den Ottolander, U. Jehn, W. Sizoo, G. L. Castoldi, S.
Fenu, and V. Liso. Cytogenetic committee: A. Hagemeijer,
G. Alimena, A Bernheim, and A. Zaccaria. Study coordina-
tor: R. Zittoun. Statistician: S. Suciu. Data managers: G.
Solbu and M. Dardenne.
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